AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...

Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of ...

In August 2025, digital assets platform Gemini claims that it became the first major crypto exchange to support Zcash unified ...

As the C language, which forms the basis of critical global software like operating systems, faces security limitations, ...

This study offers a valuable advance for neuroscience by extending a visualization tool that enables intuitive assessment of how dendritic and synaptic currents shape the output of neurons. The ...

For consumers, however, the incentives look weaker. Credit cards offer rich rewards programs, while deposits and money-market funds pay interest. By contrast, the GENIUS Act explicitly prohibits ...

But stablecoin's future might hinge on whether it becomes mainstream digital money for low-cost payments or a tool for a growing universe of risky leveraged finance. For widespread stablecoin adoption ...

Labor markets in Central America and the Dominican Republic face limited direct impacts from technological advancements ...

Effective monitoring of development aid is the foundation for assessing the alignment of flows with their intended ...